Get started
Author

Hui Yuwen

Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis
2017 · Yun-Chi Tang, Hui Yuwen, et al. · Cancer Research · 51
PDF
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al. · Cancer Research · 21
Abstract 2604: The novel ATR inhibitor ATG-018 is efficacious in preclinical cancer models
2022 · Hui Yuwen, Ya Kong, et al. · Cancer Research · 4
893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation
2021 · Hui Yuwen, Tengteng Li, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
1397 ATG 027 a first in class B7 H3 PD L1 bispecific antibody shows potent T cell activation capability and in vivo anti tumor efficacy
2022 · Hui Yuwen, Tengteng Li, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 6343: AnTenGagerTM, a novel “2+1” T cell engager platform, enables conditional T cell activation with reduced risk of CRS
2024 · Bing Hou, Hui Yuwen, et al. · Cancer Research · 1
A Novel Dual-targeting OX40L and IL-13 Bispecific Antibody with Synergistic Effect for Atopic Dermatitis Treatment 2255160
2026 · Hui Yuwen, Hongyan Shang, et al. · The Journal of Immunology
Abstract 5601: LBL-061: A novel EGFR×PD-L1 targeted drug conjugate for the treatment of multiple solid tumors
2026 · Yurong Qin, Yang Ye, et al. · Cancer Research
Abstract 5857: LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer
2026 · Yang Ye, Yurong Qin, et al. · Cancer Research
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Abstract 2372: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML
2024 · Ao Sun, Mengshi Gao, et al. · Cancer Research
1112 Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4–1BB bispecific antibody
2023 · Yunkai Zhang, Hui Yuwen, et al. · Journal for ImmunoTherapy of Cancer
PDF
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potentin vivoanti-tumor efficacy with low cytokine release
2023 · Hui Yuwen, Tengteng Li, et al. · Journal for ImmunoTherapy of Cancer
PDF
1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
2023 · Hui Yuwen, Tengteng Li, et al. · Journal for ImmunoTherapy of Cancer
PDF
Table S1 to S3 from Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis
2023 · Yun-Chi Tang, Hui Yuwen, et al.
Supplemental Figure 7 from Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis
2023 · Yun-Chi Tang, Hui Yuwen, et al.
Supplemental Figure 3 from Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis
2023 · Yun-Chi Tang, Hui Yuwen, et al.
PDF
Supplemental Figure 5 from Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis
2023 · Yun-Chi Tang, Hui Yuwen, et al.
PDF
Works count: 36
Citation count: 83
H-index: 4
I10-index: 2
Year
Topic
Type